1-(Cyanomethyl)-2,3-dihydroindene-1-carbonitrile | 81962-27-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 1-(Cyanomethyl)-2,3-dihydroindene-1-carbonitrile
• CAS: 81962-27-8
• 化学式: C₁₂H₁₀N₂
• 分子量: 182.225
• InChiKey: QDXWDVPSKWHIDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  47.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(Cyanomethyl)-2,3-dihydroindene-1-carbonitrile 在 lithium aluminium tetrahydride 、 硫酸 作用下， 以 四氢呋喃 、 溶剂黄146 为溶剂， 生成 2,3-dihydrospiro(1H-indene-1,3'-pyrrolidine)
  参考文献：
  名称：

  被设计为Profdol刚性类似物的某些螺[茚满-1,3'-吡咯烷]衍生物的合成和镇痛活性

  摘要：

  合成了螺环[茚满-1,3'-吡咯烷]的芳香族羟基化衍生物，设计为异丙酚的构象受限类似物，并在小鼠中进行了镇痛和其他中枢神经系统活动的药理学评估。在扭体试验和热板试验中，合成的化合物均不如普萘洛尔有效，但4-羟基衍生物在试验中表现出可待因水平的镇痛作用。

  DOI：

  10.1002/jps.2600710306
• 作为产物：
  描述：

  Aethyl-1-indanylidencyanoacetat 、 氰化钾 以 乙醇 、 水 为溶剂， 以83.5%的产率得到1-(Cyanomethyl)-2,3-dihydroindene-1-carbonitrile
  参考文献：
  名称：

  被设计为Profdol刚性类似物的某些螺[茚满-1,3'-吡咯烷]衍生物的合成和镇痛活性

  摘要：

  合成了螺环[茚满-1,3'-吡咯烷]的芳香族羟基化衍生物，设计为异丙酚的构象受限类似物，并在小鼠中进行了镇痛和其他中枢神经系统活动的药理学评估。在扭体试验和热板试验中，合成的化合物均不如普萘洛尔有效，但4-羟基衍生物在试验中表现出可待因水平的镇痛作用。

  DOI：

  10.1002/jps.2600710306

文献信息

• SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS
  申请人：Bertani Barbara

  公开号：US20100063078A1

  公开（公告）日：2010-03-11

  The present invention relates to novel compounds of formula (I) or salts thereof: wherein A is a substituent selected in the group consisting of P, P1, P2 and P3 wherein P is P1 is P2 is P3 is p is an integer ranging from 0 to 4; R 4 is selected in the group consisting of halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl, SF 5 and a 5- or 6-membered monocyclic heteroaryl group; and when p is an integer ranging from 2 to 4, each R 4 may be the same or different; R 2 is hydrogen or C 1-4 alkyl; q is 3, 4 or 5; n is 0, 1 or 2; X is —CR 1 R 3 — or —O—; R 1 is selected in the group consisting of hydrogen, C 1-4 alkyl and fluorine; R 3 is selected in the group consisting of hydrogen, C 1-4 alkyl and fluorine; R 5 is selected in the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, C 3-7 cycloalkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and NR′R″; or R 5 is a phenyl group, a 5-14 membered heterocyclic group; and any of such phenyl or heterocyclic group is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; R 6 is selected in the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, C 3-7 cycloalkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and NR′R″; or R 6 is a phenyl group, a 5-14 membered heterocyclic group and any of such phenyl or heterocyclic group is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; R 7 is selected in the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, C 3-7 cycloalkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and NR′R″; or R 7 is a phenyl group, a 5-14 membered heterocyclic group; and any of such phenyl or heterocyclic group is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; R 8 is selected in the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, C 3-7 cycloalkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and NR′R″; or R 8 is a phenyl group, a 5-14 membered heterocyclic group; and any of such phenyl or heterocyclic group is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; R 9 is selected in the group consisting of hydrogen, a phenyl group, a heterocyclyl group, a 5- or 6-membered monocyclic heteroaryl group, and a 8- to 11-membered heteroaryl bicyclic, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy and C 1-4 alkanoyl; R 10 is C 1-4 alkyl; R 11 is hydrogen or C 1-4 alkyl; R′ is H, C 1-4 alkyl or C 1-4 alkanoyl; R″ is defined as R′; R′ and R″ taken together with the interconnecting nitrogen atom may form a 5-, 6-membered saturated or unsaturated heterocyclic ring; wherein R 5 , R 6 , R 7 and R 8 are not simultaneously other than hydrogen; wherein only one R 2 group ma be different from hydrogen and wherein when n is 0, X is a group —CR 1 R 3 —; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D 3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or to enhance cognition.

  本发明涉及公式（I）的新化合物或其盐：其中A是从P，P1，P2和P3组成的取代基的选择，其中P是，P1是，P2是，P3是，p是0到4的整数；R4被选择在卤素，羟基，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4烷酰基，SF5和5-或6-成员的单环杂芳基组成的群中；当p是2到4的整数时，每个R4可以相同或不同；R2是氢或C1-4烷基；q是3，4或5；n是0，1或2；X是—CR1R3—或—O—；R1被选择在氢，C1-4烷基和氟中；R3被选择在氢，C1-4烷基和氟中；R5被选择在氢，卤素，羟基，氰基，C1-4烷基，C3-7环烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4烷酰基和NR′R″的群中；或R5是苯基，5-14个成员的杂环基；任何这样的苯基或杂环基可以选择地被1，2，3或4个取代基所取代，所述取代基被选择在卤素，氰基，卤代C1-4烷基，C1-4烷氧基，C1-4烷酰基和SF5的群中；R6被选择在氢，卤素，羟基，氰基，C1-4烷基，C3-7环烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4烷酰基和NR′R″的群中；或R6是苯基，5-14个成员的杂环基；任何这样的苯基或杂环基可以选择地被1，2，3或4个取代基所取代，所述取代基被选择在卤素，氰基，卤代C1-4烷基，C1-4烷氧基，C1-4烷酰基和SF5的群中；R7被选择在氢，卤素，羟基，氰基，C1-4烷基，C3-7环烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4烷酰基和NR′R″的群中；或R7是苯基，5-14个成员的杂环基；任何这样的苯基或杂环基可以选择地被1，2，3或4个取代基所取代，所述取代基被选择在卤素，氰基，卤代C1-4烷基，C1-4烷氧基，C1-4烷酰基和SF5的群中；R8被选择在氢，卤素，羟基，氰基，C1-4烷基，C3-7环烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4烷酰基和NR′R″的群中；或R8是苯基，5-14个成员的杂环基；任何这样的苯基或杂环基可以选择地被1，2，3或4个取代基所取代，所述取代基被选择在卤素，氰基，卤代C1-4烷基，C1-4烷氧基，C1-4烷酰基和SF5的群中；R9被选择在氢，苯基，杂环基，5-或6-成员的单环杂芳基和8-到11-成员的杂芳双环中的一个，其中任何这样的基团可以选择地被1，2，3或4个取代基所取代，所述取代基被选择在卤素，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基和C1-4烷酰基的群中；R10是C1-4烷基；R11是氢或C1-4烷基；R′是H，C1-4烷基或C1-4烷酰基；R″被定义为R′；R′和R″与相互连接的氮原子一起可以形成5-，6-成员的饱和或不饱和杂环环；其中R5，R6，R7和R8不同时为除氢外的其他基团；其中只有一个R2基团可能与氢不同，当n为0时，X是一个—CR1R3—基团；用于其制备的过程，用于这些过程的中间体，包含它们的制药组合物以及它们作为多巴胺D3受体调节剂的用途，例如用于治疗药物依赖症，作为抗精神病药物，用于治疗强迫症谱系障碍，早泄或增强认知能力。
• CROOKS, P. A.;SOMMERVILLE, R., J. PHARM. SCI., 1982, 71, N 3, 291-294
  作者：CROOKS, P. A.、SOMMERVILLE, R.

  DOI：——

  日期：——
• US8030322B2
  申请人：——

  公开号：US8030322B2

  公开（公告）日：2011-10-04
• The Synthesis and Analgesic Activities of Some Spiro[indan-l,3'-pyrrolidine] Derivatives Designed as Rigid Analogs of Profadol
  作者：P.A. crooks、R. Sommerville

  DOI：10.1002/jps.2600710306

  日期：1982.3

  Aromatic hydroxylated derivatives of spiro[indan-1,3'-pyrrolidine], designed as conformationally restricted analogs of profadol, were synthesized and pharmacologically evaluated in mice for analgesia and other central nervous system activities. None of the compounds synthesized were as potent as profadol in writhing and hot plate tests, but the 4-hydroxy derivative exhibited codeine-level analgesia

  合成了螺环[茚满-1,3'-吡咯烷]的芳香族羟基化衍生物，设计为异丙酚的构象受限类似物，并在小鼠中进行了镇痛和其他中枢神经系统活动的药理学评估。在扭体试验和热板试验中，合成的化合物均不如普萘洛尔有效，但4-羟基衍生物在试验中表现出可待因水平的镇痛作用。